Overall rank by patents
#37,305
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Satiogen Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, active 2016–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
7
Total patents granted
4
CPC technology areas
15.3
Avg claims per patent
-60%
5-year filing velocity
The verdict
Satiogen holds 7 US patents across 4 technology areas, rank #37,305 of 50,000 tracked assignees.
- #37,305
- of 50,000 US assignees by volume
- Top 82%
- by Innovation Score (25.6/100)
- 15.3
- avg claims per patent
- -60%
- filing velocity, last 5 yrs
Portfolio overview
Satiogen Pharmaceuticals, Inc. has been granted 7 US utility patents between 2016 and 2022, placing Satiogen Pharmaceuticals, Inc. at rank #37,305 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Satiogen Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Satiogen sits between SAOL International Limited (7 patents, rank #37,301) and Scaeva Technologies, Inc. (7 patents, rank #37,309) - the closest US assignees by grant volume. The composite Innovation Score of 25.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 5 in the 2015–2019 window, a -60% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Satiogen Pharmaceuticals, Inc.'s 15.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Satiogen Pharmaceuticals, Inc. against peers pursuing similar technology classes.
Who files at Satiogen's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- SAOL International
SAOL INTERNATIONAL LIMITED
7 patents
- Sarah Wells
SARAH WELLS, LLC
7 patents
- Sarine Color
SARINE COLOR TECHNOLOGIES LTD.
7 patents
- Sarine
SARINE TECHNOLOGIES LTD.
7 patents
- Sauermann Industr…
SAUERMANN INDUSTRIE
7 patents
- SBCD Enterprises
SBCD Enterprises LLC
7 patents
- SBS Technology AS
SBS TECHNOLOGY AS
7 patents
- Scaeva
SCAEVA Technologies, Inc.
7 patents
- Satiogen Pharmace… ◀
SATIOGEN PHARMACEUTICALS, INC.
7 patents
What this shows Satiogen holds 7 patents at rank #37,305, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Satiogen
By rank, the assignees closest to #37,305 in granted patent volume.
- SAOL International Limited #37,301 · 7 patents
- Sarah Wells, Llc #37,302 · 7 patents
- Sarine Color Technologies Ltd. #37,303 · 7 patents
- Sarine Technologies Ltd. #37,304 · 7 patents
- Sauermann Industrie #37,306 · 7 patents
- SBCD Enterprises Llc #37,307 · 7 patents
- SBS Technology AS #37,308 · 7 patents
- Scaeva Technologies, Inc. #37,309 · 7 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Satiogen's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Satiogen's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
26 Top 82% higher than 18% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 28.6% |
| 2018 | 1 | 14.3% |
| 2019 | 2 | 28.6% |
| 2020 | 1 | 14.3% |
| 2022 | 1 | 14.3% |
Which technologies does Satiogen Pharmaceuticals, Inc. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Satiogen Pharmaceuticals, Inc. hold?
Satiogen Pharmaceuticals, Inc. holds 7 US granted patents filed between 2016 and 2022, spanning 4 technology areas.
What is Satiogen Pharmaceuticals, Inc.'s Innovation Score?
Satiogen Pharmaceuticals, Inc. has an Innovation Score of 25.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Satiogen Pharmaceuticals, Inc. focus on?
Satiogen Pharmaceuticals, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 7 patents. The company has filed patents in 4 CPC subclasses total.
Is Satiogen Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Satiogen Pharmaceuticals, Inc.'s recent filing velocity is -60% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Satiogen Pharmaceuticals, Inc.'s patents?
Satiogen Pharmaceuticals, Inc.'s patents average 15.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Satiogen Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Satiogen's 7 grants land it in the top 82% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Satiogen ranks #37,305 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.